What is the main difference between Tirzepatide and GLP-3RT?

Tirzepatide is studied as a dual GIP/GLP-1 receptor agonist, while GLP-3RT is studied as a triple GIP/GLP-1/glucagon receptor agonist. The glucagon-receptor activity is what distinguishes GLP-3RT in metabolic research.

Are Tirzepatide and GLP-3RT interchangeable in research?

No. They engage different numbers of receptor systems, so the choice depends on the research question. Both are for research use only and are not approved for human use.

COMPARISONS 6 MIN READ

Tirzepatide vs GLP-3RT: A Research Comparison

The core difference is receptor breadth: Tirzepatide is studied as a dual agonist of the GIP and GLP-1 receptors, while GLP-3RT is studied as a triple agonist that adds glucagon-receptor activity. Both are investigated within incretin signaling and energy-metabolism research models, and both are for research use only.

The core difference: dual vs triple agonism

Tirzepatide is studied as a dual agonist engaging the GIP and GLP-1 receptors. GLP-3RT is studied as a triple agonist that engages the GIP, GLP-1, and glucagon receptors. The added glucagon-receptor activity is the defining distinction between the two compounds in metabolic research.

Structure and molecular profile

Both are large, modified synthetic peptides with aminoisobutyric acid substitutions and fatty-acid acylation studied for stability. Tirzepatide is a 39-residue peptide (molecular weight near 4813 g/mol) and GLP-3RT is also a 39-residue acylated peptide (molecular weight near 4731 g/mol). Salt form and exact modifications should be confirmed against each Certificate of Analysis.

How each is studied

Research with both compounds examines insulin secretion and glucose handling via GIP and GLP-1 signaling. GLP-3RT additionally allows study of glucagon-receptor contributions to energy expenditure and lipid handling. Which compound a protocol uses depends on whether the research question involves two or three receptor systems.

The two also sit at different points on the regulatory map. Tirzepatide is an approved drug, marketed as Mounjaro and Zepbound after the SURPASS and SURMOUNT Phase 3 programs, whereas retatrutide is investigational and has been examined in the Phase 3 TRIUMPH program rather than approved. These are verifiable statements about each molecule's public status, not human-use claims for the research materials sold here.

All products are intended strictly for in-vitro laboratory research and development use only. Not for human or veterinary use, not a drug, food, or cosmetic, and not intended to diagnose, treat, cure, or prevent any disease.